Pacific Edge Ltd
NZX:PEB
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.075
0.173
|
| Price Target |
|
We'll email you a reminder when the closing price reaches NZD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Pacific Edge Ltd
Pacific Edge Ltd
Free Cash Flow
Pacific Edge Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pacific Edge Ltd
NZX:PEB
|
Free Cash Flow
-NZ$27.1m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-10%
|
|
|
Aroa Biosurgery Ltd
ASX:ARX
|
Free Cash Flow
-NZ$14.4m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
Pacific Edge Ltd
Glance View
Pacific Edge Ltd. engages in the discovery and commercialization of diagnostic and prognostic technology for the early detection and monitoring of cancer. The firm develops and commercializes diagnostic and prognostic tools for the early detection and management of cancers. The firm's segments include NZ Laboratory, US Laboratory and Research NZ & Australia. Its segments are engaged in the research and development of diagnostic and prognostic products for human cancer both in New Zealand and Australia, and operation of the laboratories used for the detection of bladder cancer in the United States and New Zealand. The company offers Cxbladder, which is a suite of non-invasive laboratory tests for the detection and the management of bladder cancer. Cxbladder includes a suite of urine-based molecular tests to determine the likelihood of bladder cancer in patients presenting with hematuria. Its pipeline includes Cxcolorectal, which is a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancer, enabling prediction of aggressiveness of the tumor.
See Also
What is Pacific Edge Ltd's Free Cash Flow?
Free Cash Flow
-27.1m
NZD
Based on the financial report for Mar 31, 2024, Pacific Edge Ltd's Free Cash Flow amounts to -27.1m NZD.
What is Pacific Edge Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-10%
Over the last year, the Free Cash Flow growth was 5%. The average annual Free Cash Flow growth rates for Pacific Edge Ltd have been -25% over the past three years , -9% over the past five years , and -10% over the past ten years .
You don't have any saved screeners yet
